title: Morbidity and mortality after neoadjuvant therapy for lung cancer: the risks of right pneumonectomy.
abstract: BACKGROUND
  The risks of complications in patients undergoing thoracotomy after neoadjuvant therapy for nonsmall cell lung cancer remain controversial. We reviewed our experience to define it further.
  
  
  METHODS
  All patients undergoing thoracotomy after induction chemotherapy from 1993 through 1999 were reviewed. Univariate and multivariate methods for logistic regression model were used to identify predictors of adverse events.
  
  
  RESULTS
  Induction chemotherapy included mitomycin, vinblastine, and cisplatin (179 patients), carboplatin and paclitaxel (152 patients), and other combinations (139 patients). Eighty-five patients (18%) received preoperative radiation. Operations were pneumonectomy (97 patients), lobectomy (297 patients), lesser resection (18 patients), and exploration only (58 patients). Total mortality was 7 of 297 (2.4%) and 11 of 97 (11.3%) for all lobectomies and pneumonectomies, respectively, but mortality was 11 of 46 (23.9%) for right pneumonectomy. Complications developed in 179 patients (38%). By multiple regression analysis, right pneumonectomy (p = 0.02), blood loss (p = 0.01), and forced expiratory volume in one second (percent predicted) (p = 0.01) predicted complications. No factor emerged to explain this high right pneumonectomy mortality rate.
  
  
  CONCLUSIONS
  Pulmonary resection after neoadjuvant therapy is associated with acceptable overall morbidity and mortality. However, right pneumonectomy is associated with a significantly increased risk and should be performed only in selected patients.
authors.affiliation: Department of Surgery, Memorial Sloan-Kettering Cancer Center, New York, New York 10021, USA.
authors.forename: J
authors.initials: J
authors.lastname: Martin
authors.forename: R J
authors.initials: RJ
authors.lastname: Ginsberg
authors.forename: A
authors.initials: A
authors.lastname: Abolhoda
authors.forename: M S
authors.initials: MS
authors.lastname: Bains
authors.forename: R J
authors.initials: RJ
authors.lastname: Downey
authors.forename: R J
authors.initials: RJ
authors.lastname: Korst
authors.forename: T L
authors.initials: TL
authors.lastname: Weigel
authors.forename: M G
authors.initials: MG
authors.lastname: Kris
authors.forename: E S
authors.initials: ES
authors.lastname: Venkatraman
authors.forename: V W
authors.initials: VW
authors.lastname: Rusch
mesh_terms: D000328:Adult; D000368:Aged; D000369:Aged, 80 and over; D002289:Carcinoma, Non-Small-Cell Lung / Q000401:mortality / Q000473:pathology / Q000601:surgery*; D003131:Combined Modality Therapy; D005260:Female; D017052:Hospital Mortality; D006801:Humans; D008175:Lung Neoplasms / Q000401:mortality / Q000473:pathology / Q000601:surgery*; D008297:Male; D008875:Middle Aged; D020360:Neoadjuvant Therapy / Q000009:adverse effects*; D009367:Neoplasm Staging; D011013:Pneumonectomy / Q000009:adverse effects*; D011183:Postoperative Complications / Q000401:mortality*; D012306:Risk; D016019:Survival Analysis